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BACKGROUND
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few 
effective long-term treatments are available. In cardiovascular trials of inhibitors 
of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested 
that such drugs may improve renal outcomes in patients with type 2 diabetes.
METHODS
In this double-blind, randomized trial, we assigned patients with type 2 diabetes 
and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 
inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated 
glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-
surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 
5000) and were treated with renin–angiotensin system blockade. The primary 
outcome was a composite of end-stage kidney disease (dialysis, transplantation, or 
a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the 
serum creatinine level, or death from renal or cardiovascular causes. Prespecified 
secondary outcomes were tested hierarchically.
RESULTS
The trial was stopped early after a planned interim analysis on the recommenda-
tion of the data and safety monitoring committee. At that time, 4401 patients had 
undergone randomization, with a median follow-up of 2.62 years. The relative risk 
of the primary outcome was 30% lower in the canagliflozin group than in the 
placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respec-
tively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). 
The relative risk of the renal-specific composite of end-stage kidney disease, a 
doubling of the creatinine level, or death from renal causes was lower by 34% 
(hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-
stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; 
P = 0.002). The canagliflozin group also had a lower risk of cardiovascular death, 
myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) 
and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; 
P<0.001). There were no significant differences in rates of amputation or fracture.
CONCLUSIONS
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and 
cardiovascular events was lower in the canagliflozin group than in the placebo group 
at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; 
CREDENCE ClinicalTrials.gov number, NCT02065791.)
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The increasing prevalence of type 2 diabetes during recent decades1 is the primary factor accounting for the substan-
tial global increase in end-stage kidney disease. 
Currently, more than 3 million people worldwide 
are estimated to be receiving treatment for kid-
ney failure, with predictions that the number will 
increase to more than 5 million by 2035.2 The 
only currently approved treatment for renopro-
tection in patients with type 2 diabetes is renin–
angiotensin system blockade, which was first 
shown to be effective 18 years ago.3,4
Inhibitors of sodium–glucose cotransporter 2 
(SGLT2) were developed to lower blood glucose 
levels in patients with type 2 diabetes. In several 
trials designed to meet regulatory requirements for 
cardiovascular safety, investigators found reduc-
tions in cardiovascular events with SGLT2 inhibi-
tors.5-7 Secondary and exploratory analyses of 
these trials suggested that SGLT2 inhibition might 
improve renal outcomes; however, some uncer-
tainty persisted, since relatively few patients 
reached end-stage kidney disease and the trial 
patients were at low risk for kidney failure.7-9 We 
designed the CREDENCE (Canagliflozin and Re-
nal Events in Diabetes with Established Nephrop-
athy Clinical Evaluation) trial to assess the effects 
of the SGLT2 inhibitor canaglif lozin on renal 
outcomes in patients with type 2 diabetes and 
albuminuric chronic kidney disease.
Me thods
Trial Design and Oversight
Details regarding the design of this randomized, 
double-blind, placebo-controlled, multicenter clini-
cal trial have been published previously.10 The 
protocol (available with the full text of this article 
at NEJM.org) was reviewed by relevant regulatory 
authorities and ethics committees responsible 
for each trial site. The trial was sponsored by 
Janssen Research and Development as a collabo-
ration between the sponsor, an academic-led 
steering committee, and an academic research 
organization, George Clinical, with operational 
implementation by IQVIA, a contract research 
organization. Technical editorial assistance pro-
vided by MedErgy was funded by the sponsor.
Members of the steering committee designed 
the trial, supervised its conduct, and were respon-
sible for reporting the results. Analyses were per-
formed by the sponsor and independently con-
firmed at George Clinical with the use of original 
data. The first and last authors drafted the first 
version of the manuscript, and all the authors 
contributed to revisions. The decision to submit 
the manuscript for publication was made jointly 
by all the authors, who vouch for the complete-
ness and accuracy of the data and for the fidel-
ity of the trial to the protocol.
Patients
Patients were eligible if they were at least 30 years 
of age and had type 2 diabetes, with a glycated 
hemoglobin level of 6.5 to 12.0% (6.5 to 10.5% 
in Germany, according to a country amendment). 
They were also required to have chronic kidney 
disease, defined as an estimated glomerular fil-
tration rate (GFR, as calculated by the Chronic 
Kidney Disease Epidemiology Collaboration for-
mula) of 30 to <90 ml per minute per 1.73 m2 of 
body-surface area and albuminuria (urinary albu-
min-to-creatinine ratio, >300 to 5000, with albu-
min measured in milligrams and creatinine in 
grams), as measured in a central laboratory. There 
was a prespecified plan to include approximately 
60% of patients with an estimated GFR of 30 to 
<60 ml per minute per 1.73 m2.
All the patients were required to be receiving a 
stable dose of an angiotensin-converting–enzyme 
inhibitor or angiotensin-receptor blocker for at 
least 4 weeks before randomization; a stable dose 
was considered to be either the maximum labeled 
dose or a dose not associated with unacceptable 
side effects. Dual-agent treatment with an angio-
tensin-converting–enzyme inhibitor and an angio-
tensin-receptor blocker, a direct renin inhibitor, 
or a mineralocorticoid-receptor antagonist was not 
allowed.
Patients who had suspected nondiabetic kid-
ney disease or type 1 diabetes, had been treated 
with immunosuppression for kidney disease, or 
had a history of dialysis or kidney transplantation 
were excluded. Full inclusion and exclusion crite-
ria are described in the Supplementary Appendix, 
available at NEJM.org. All the patients provided 
written informed consent.
Trial Procedures
The patients were prescreened to determine the 
estimated GFR and urinary albumin-to-creatinine 
ratio by medical-chart review or prospective labo-
ratory assessment. The patients who met the eli-
gibility criteria at screening were included in a 
A Quick Take is 
available at 
NEJM.org 
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2-week, single-blind, placebo run-in period and 
were eligible for randomization if they had re-
ceived at least 80% of single-blind placebo dur-
ing the run-in period.
The patients were randomly assigned in a 
double-blind fashion (1:1) to receive either cana-
gliflozin (100 mg orally once daily) or matching 
placebo with the use of randomly permuted blocks, 
with stratification according to the category of 
estimated GFR (30 to <45 ml, 45 to <60 ml, or 
60 to <90 ml per minute per 1.73 m2) at screen-
ing. The administration of canagliflozin or pla-
cebo was to be continued until trial completion, 
initiation of dialysis, kidney transplantation, 
occurrence of diabetic ketoacidosis, pregnancy, 
or receipt of a disallowed therapy.
After randomization, trial visits were con-
ducted at weeks 3, 13, and 26 and then alternated 
between telephone calls and in-clinic visits at 
13-week intervals. Additional testing of blood at 
either the central or local laboratory and safety 
assessments were permitted at any time at the 
discretion of the investigators. The use of other 
background therapy for glycemic management 
and control of cardiovascular risk factors was rec-
ommended in accordance with local guidelines.
During the trial, an increased risk of lower 
limb amputation was identified in another trial 
of canagliflozin.5 A protocol amendment for the 
present trial in May 2016 asked investigators to 
examine patients’ feet at each trial visit and tem-
porarily interrupt the assigned treatment in pa-
tients with any active condition that might lead 
to amputation.
Outcomes
The primary outcome was a composite of end-
stage kidney disease (dialysis for at least 30 days, 
kidney transplantation, or an estimated GFR of 
<15 ml per minute per 1.73 m2 sustained for at 
least 30 days according to central laboratory as-
sessment), doubling of the serum creatinine level 
from baseline (average of randomization and 
prerandomization value) sustained for at least 30 
days according to central laboratory assessment, 
or death from renal or cardiovascular disease.
Secondary outcomes that were planned for 
sequential hierarchical testing were specified in 
the following order: first, a composite of cardio-
vascular death or hospitalization for heart failure; 
second, a composite of cardiovascular death, 
myocardial infarction, or stroke; third, hospital-
ization for heart failure; fourth, a composite of 
end-stage kidney disease, doubling of the serum 
creatinine level, or renal death; fifth, cardiovas-
cular death; sixth, death from any cause; and 
seventh, a composite of cardiovascular death, 
myocardial infarction, stroke, or hospitalization 
for heart failure or for unstable angina. All other 
efficacy outcomes were exploratory.
Safety evaluations included laboratory testing 
and assessments of adverse events. All renal and 
cardiovascular outcomes that were part of the 
primary and secondary outcomes, as well as key 
safety outcomes (fractures, pancreatitis, keto-
acidosis, and renal-cell carcinoma), were adjudi-
cated by independent adjudication committees 
whose members were unaware of trial-group 
assignments. (Details regarding trial outcomes 
are provided in the Supplementary Appendix.)
Statistical Analysis
The trial was designed to be event-driven, with the 
enrollment of at least 4200 patients (844 events) 
required to provide a power of 90% to detect a 
risk of the primary outcome that was 20% lower 
in the canagliflozin group than in the placebo 
group at an alpha level of 0.045 after adjustment 
for one interim analysis. A single interim analy-
sis was to be conducted by an independent data 
monitoring committee after the primary out-
come had occurred in 405 patients. Prespecified 
stopping guidance that was provided to the data 
monitoring committee by the steering commit-
tee proposed possible recommendation of early 
cessation if clear evidence of benefit was ob-
served for the primary outcome (P<0.01) and the 
composite of end-stage kidney disease or death 
from renal or cardiovascular causes (P<0.025), 
with consideration of the overall balance of risks 
and benefits.
In the intention-to-treat population, we used 
a stratified Cox proportional-hazards model to 
analyze the primary and secondary outcomes, 
according to the category of estimated GFR at 
screening. Data were censored on October 30, 
2018, or the date of last known contact, which 
included the last trial visit (either in-clinic or 
telephone) or the date of alternative contact con-
firming that the patient was alive at the time of 
trial closure.
If the trial was to be stopped at the interim 
analysis, the significance level for the primary 
outcome would be determined by the alpha spend-
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ing function (two-sided level of 0.022 for 585 
events), and the secondary outcomes would be 
tested at a two-sided level of 0.038, to account 
for type I error inflation in the group sequential 
design. Subgroup analyses were assessed by 
tests for the interaction between the trial group 
and the subgroup in stratified Cox proportional-
hazards models without adjustment for multiple 
testing. We used mixed models for repeated mea-
sures to analyze changes in intermediate out-
comes over time in the on-treatment analysis 
population (unless otherwise noted), assuming 
an unstructured covariance and adjusting for the 
baseline value, trial group, category of estimated 
GFR at screening, trial visit, interaction between 
trial group and visit, and interaction between 
baseline value and visit. All available measure-
ments were used with no distinction made for 
missing outcomes for patients who were alive 
and outcomes that were not observed because of 
death. Slope analyses regarding the estimated 
GFR for the acute phase (baseline to week 3), 
chronic phase (week 3 to end of treatment), and 
total slope through week 130 are described in 
the Supplementary Appendix.
We used the data set for all treated patients 
through 30 days after the last dose for the safety 
analyses (on-treatment analysis) and used the on-
study analysis that included all treated patients 
through the end of the trial to evaluate selected 
adverse events, including cancer, amputation, and 
fracture.
We calculated the numbers of patients who 
needed to be treated to prevent one event during 
2.5 years as the reciprocal of the between-group 
difference in cumulative incidence at 2.5 years on 
the basis of the Kaplan–Meier curve. All analyses 
were performed with the use of SAS software, 
version 9.4 (SAS Institute).
R esult s
Patients
From March 2014 through May 2017, a total of 
12,900 patients were screened and 4401 under-
went randomization at 690 sites in 34 countries 
(Fig. S1 in the Supplementary Appendix). The 
baseline characteristics of the patients were simi-
lar in the two groups (Table 1, and Tables S1 and 
S2 in the Supplementary Appendix).10 The mean 
age was 63 years, and 33.9% of the patients were 
women. The mean glycated hemoglobin value 
was 8.3%, the mean estimated GFR was 56.2 ml 
per minute per 1.73 m2, and the median urinary 
albumin-to-creatinine ratio was 927, with albu-
min measured in milligrams and creatinine in 
grams.
The requisite number of primary outcome 
events to trigger the interim analysis were ac-
crued by July 2018. The data monitoring com-
mittee advised the steering committee members 
that the prespecified efficacy criteria for early 
cessation had been achieved and recommended 
that the trial be stopped. The trial leadership 
accepted this recommendation, the patients 
were recalled for final visits, and the trial was 
concluded.
At the trial conclusion at a median follow-up 
of 2.62 years (range, 0.02 to 4.53), 1201 patients 
(27.3%) in the two groups had discontinued ther-
apy (Table S3 and Figs. S1 and S2 in the Supple-
mentary Appendix); the rate of adherence to the 
trial regimen was 84% during follow-up. A total 
of 4361 patients (99.1%) were either alive with 
follow-up at the end of the trial or had died be-
fore the final follow-up visit. Consent was with-
drawn by 16 patients (0.4%), and vital status was 
ascertained for all but 6 patients (4395 [99.9%]).
Effect on the Primary Outcome and Renal 
Components
The event rate of the primary composite out-
come of end-stage kidney disease, doubling of 
the serum creatinine level, or renal or cardiovas-
cular death was significantly lower in the cana-
gliflozin group than in the placebo group (43.2 
and 61.2 per 1000 patient-years, respectively), 
which resulted in a 30% lower relative risk (haz-
ard ratio, 0.70; 95% confidence interval [CI], 
0.59 to 0.82; P = 0.00001) (Table 2 and Fig. 1A). 
The effects were consistent across regions and 
other prespecified subgroups (Fig. 2, and Fig. S3 
in the Supplementary Appendix) and for the com-
ponents of end-stage kidney disease (hazard ra-
tio, 0.68; 95% CI, 0.54 to 0.86; P = 0.002) (Table 2 
and Fig. 1C). The effects were also consistent 
across renal components, including the doubling 
of the serum creatinine level (hazard ratio, 0.60; 
95% CI, 0.48 to 0.76; P<0.001) (Table 2) and the 
exploratory outcome of dialysis, kidney trans-
plantation, or renal death (hazard ratio, 0.72; 
95% CI, 0.54 to 0.97) (Table 2 and Fig. 1D). 
Nearly identical results were shown in sensitivity 
analyses that included imputation of missing 
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data (hazard ratio, 0.69; 95% CI, 0.59 to 0.82) or 
that were adjusted for competing risks (hazard 
ratio, 0.70; 95% CI, 0.59 to 0.82).
Secondary and Exploratory Outcomes
Patients in the canagliflozin group also had a 
lower risk of several secondary outcomes tested 
in a hierarchical fashion (Table 2), including the 
composites of cardiovascular death or hospital-
ization for heart failure (hazard ratio, 0.69; 95% 
CI, 0.57 to 0.83; P<0.001), cardiovascular death, 
myocardial infarction, or stroke (hazard ratio, 
0.80; 95% CI, 0.67 to 0.95; P = 0.01), and hospi-
talization for heart failure (hazard ratio, 0.61; 
95% CI, 0.47 to 0.80; P<0.001). The relative risk 
of the composite of end-stage kidney disease, 
doubling of the serum creatinine level, or renal 
death was lower by 34% in the canaglif lozin 
group (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; 
P<0.001) (Table 2 and Fig. 1B).
There was no significant between-group dif-
ference in the risk of cardiovascular death (haz-
ard ratio, 0.78; 95% CI, 0.61 to 1.00; P = 0.05) 
(Table 2 and Fig. 1E), so the differences in all 
subsequent outcomes in the hierarchical testing 
sequence were not formally tested. The hazard 
ratio for death from any cause was 0.83 (95% CI, 
0.68 to 1.02) (Table 2 and Fig. 1F); for the com-
posite of cardiovascular death, myocardial in-
farction, stroke, or hospitalization for heart 
failure or unstable angina, the hazard ratio was 
0.74 (95% CI, 0.63 to 0.86) (Table 2).
Characteristic
Canagliflozin 
(N = 2202)
Placebo 
(N = 2199)
All Patients 
(N = 4401)
Age — yr 62.9±9.2 63.2±9.2 63.0±9.2
Female sex — no. (%) 762 (34.6) 732 (33.3) 1494 (33.9)
Race or ethnic group — no. (%)†
White 1487 (67.5) 1444 (65.7) 2931 (66.6)
Black 112 (5.1) 112 (5.1) 224 (5.1)
Asian 425 (19.3) 452 (20.6) 877 (19.9)
Other 178 (8.1) 191 (8.7) 369 (8.4)
Current smoker — no. (%) 341 (15.5) 298 (13.6) 639 (14.5)
Hypertension — no. (%) 2131 (96.8) 2129 (96.8) 4260 (96.8)
Heart failure — no. (%) 329 (14.9) 323 (14.7) 652 (14.8)
Duration of diabetes — yr 15.5±8.7 16.0±8.6 15.8±8.6
Cardiovascular disease — no. (%) 1113 (50.5) 1107 (50.3) 2220 (50.4)
Amputation — no. (%) 119 (5.4) 115 (5.2) 234 (5.3)
Body-mass index‡ 31.4±6.2 31.3±6.2 31.3±6.2
Blood pressure — mm Hg
Systolic 139.8±15.6 140.2±15.6 140.0±15.6
Diastolic 78.2±9.4 78.4±9.4 78.3±9.4
Glycated hemoglobin — % 8.3±1.3 8.3±1.3 8.3±1.3
Estimated GFR — ml/min/1.73 m2§ 56.3±18.2 56.0±18.3 56.2±18.2
Median urinary albumin-to-creatinine ratio (IQR)¶ 923 
(459–1794)
931 
(473–1868)
927 
(463–1833)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile 
range.
†  Race or ethnic group was reported by the patients. The designation “other” includes American Indian or Alaska Native, 
Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  The baseline estimated glomerular filtration rate (GFR) was missing for one patient in the canagliflozin group.
¶  The albumin-to-creatinine ratio was calculated with albumin measured in milligrams and creatinine measured in 
grams.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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Effects on Safety Outcomes
Rates of adverse events and serious adverse events 
were similar overall in the canagliflozin group 
and the placebo group (Table 2, and Tables S4 
and S5 in the Supplementary Appendix). There 
was no significant difference in the risk of lower-
limb amputation, with rates of 12.3 versus 11.2 
per 1000 patient-years in the canagliflozin group 
and the placebo group, respectively (hazard ra-
tio, 1.11; 95% CI, 0.79 to 1.56). Rates of fracture 
were also similar in the two groups (hazard ra-
tio, 0.98; 95% CI, 0.70 to 1.37). Rates of diabetic 
ketoacidosis were low but higher in the cana-
gliflozin group than in the placebo group (2.2 vs. 
0.2 per 1000 patient-years) (Table S6 in the Sup-
plementary Appendix).
Effect on Intermediate Outcomes
For glycated hemoglobin, the least-squares mean 
level at 13 weeks was lower in the canaglif lozin 
group than in the placebo group by 0.31 per-
centage points (95% CI, 0.26 to 0.37), and the 
between-group difference narrowed thereafter, 
with an overall mean difference in the reduc-
tion throughout the trial of 0.25 percentage 
points (95% CI, 0.20 to 0.31) (Fig. S4 in the 
Supplementary Appendix). On average, levels 
were lower in the canaglif lozin group for sys-
tolic blood pressure (by 3.30 mm Hg; 95% CI, 
2.73 to 3.87), diastolic blood pressure (by 0.95 
mm Hg; 95% CI, 0.61 to 1.28), and body weight 
(by 0.80 kg; 95% CI, 0.69 to 0.92). The geomet-
ric mean of the urinary albumin-to-creatinine 
ratio was lower by 31% (95% CI, 26 to 35) on 
average during follow-up in the canaglif lozin 
group (Fig. 3A).
The least-squares mean (±SE) change in the 
estimated GFR slope was less in the canagliflozin 
group than in the placebo group (–3.19±0.15 vs. 
–4.71±0.15 ml per minute per 1.73 m2 per year), 
for a between-group difference of 1.52 ml per 
minute per 1.73 m2 per year (95% CI, 1.11 to 1.93) 
(Fig. 3B). During the first 3 weeks, there was a 
greater reduction in the estimated GFR in the 
canagliflozin group than in the placebo group 
(–3.72±0.25 vs. –0.55±0.25 ml per minute per 
1.73 m2), for a between-group difference of 
–3.17 ml per minute per 1.73 m2 (95% CI, –3.87 
to –2.47). Thereafter, the decline in the esti-
mated GFR was slower in the canaglif lozin 
group than in the placebo group (–1.85±0.13 vs. 
–4.59±0.14 ml per minute per 1.73 m2 per year), A
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for a difference of 2.74 ml per minute per 1.73 m2 
per year (95% CI, 2.37 to 3.11).
Projected Estimated Effects
On the basis of our trial data, we estimate that 
among 1000 patients in our trial treated for 2.5 
years, the primary composite outcome of end-
stage kidney disease, doubling of the serum 
creatinine level, or renal or cardiovascular death 
would occur in 47 fewer patients in the cana-
gliflozin group than in the placebo group (num-
ber needed to treat [NNT], 22; 95% CI, 15 to 38), 
including 36 fewer composite renal outcomes of 
end-stage kidney disease, doubling of the serum 
creatinine level, or renal death (NNT, 28; 95% 
CI, 19 to 54) and 24 fewer end-stage kidney-
disease events (NNT, 43; 95% CI, 26 to 121). 
Canaglif lozin treatment would also prevent 22 
Figure 2. Subgroup Analysis, According to Estimated Glomerular Filtration Rate (GFR) at Screening and Albuminuria at Baseline.
Shown are the primary composite outcome and renal-specific composite outcome, according to the patients’ estimated GFR at screen-
ing and urinary albumin-to-creatinine ratio (UACR) at baseline, in the canagliflozin group and the placebo group. The albumin-to-creati-
nine ratio was calculated with albumin measured in milligrams and creatinine measured in grams. CV denotes cardiovascular, and ESKD 
end-stage kidney disease.
0.50 1.00 2.00 4.00
Placebo
Better
Canagliflozin
Better
Primary composite outcome of ESKD,
doubling of serum creatinine,
or renal or CV death
Screening estimated GFR
30 to <45 ml/min/1.73 m2
45 to <60 ml/min/1.73 m2
60 to <90 ml/min/1.73 m2
Baseline UACR
≤1000
>1000
Renal-specific composite outcome
of ESKD, doubling of serum
creatinine, or renal death
Screening estimated GFR
30 to <45 ml/min/1.73 m2
45 to <60 ml/min/1.73 m2
60 to <90 ml/min/1.73 m2
Baseline UACR
≤1000
>1000
Canagliflozin Hazard Ratio (95% CI)PlaceboSubgroup
0.25
P Value for
Interaction
119/657  
56/640
70/905
  69/1185
176/1017
85/657
33/640
35/905
  29/1185
124/1017
153/656  
102/639  
85/904
  88/1163
252/1036
115/656  
66/639
43/904
  31/1163
193/1036
72.2
33.4
29.9
22.0
69.6
51.6
19.7
14.9
9.2
49.1
95.4
63.1
36.5
28.8
100.8
71.7
40.8
18.5
10.2
77.2
0.75 (0.59–0.95)
0.52 (0.38–0.72)
0.82 (0.60–1.12)
0.76 (0.55–1.04)
0.67 (0.55–0.81)
0.71 (0.53–0.94)
0.47 (0.31–0.72)
0.81 (0.52–1.26)
0.90 (0.54–1.50)
0.61 (0.49–0.76)
0.11
0.49
0.18
0.16
no. of patients/total no.
Canagliflozin Placebo
events/1000 patient-yr
Figure 1 (facing page). Primary Composite, Renal,  
and Mortality Outcomes.
Panel A shows the primary composite outcome of 
 end-stage kidney disease, doubling of the serum cre-
atinine level, or renal or cardiovascular death in the 
canagliflozin group and the placebo group. Panel B 
shows the renal-specific composite outcome of end-
stage kidney disease, doubling of serum creatinine 
 level, or renal death. Panel C shows end-stage kidney 
disease, which was defined as the initiation of dialysis 
for at least 30 days, kidney transplantation, or an esti-
mated glomerular filtration rate of less than 15 ml per 
minute per 1.73 m2 of body-surface area that was sus-
tained for at least 30 days, according to central labo-
ratory assessment. Panel D shows the initiation of 
 dialysis, kidney transplantation, or renal death, which 
was an exploratory outcome. Panel E shows death 
from cardiovascular causes, and Panel F death from 
any cause. The insets show the same data on an ex-
panded y axis.
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hospitalizations for heart failure (NNT, 46; 95% 
CI, 29 to 124) and 25 composite events of cardio-
vascular death, myocardial infarction, or stroke 
(NNT, 40; 95% CI, 23 to 165).
Discussion
In this trial, we found that patients with type 2 
diabetes and chronic kidney disease who re-
ceived canagliflozin had a lower risk of the pri-
mary composite outcome of end-stage kidney 
disease, doubling of the serum creatinine level, 
or death from renal or cardiovascular causes 
than those who received placebo. Patients in the 
canagliflozin group also had a lower risk of end-
stage kidney disease, hospitalization for heart 
failure, and the composite of cardiovascular 
death, myocardial infarction, or stroke. These 
results indicate that canagliflozin may be an ef-
fective treatment option for renal and cardiovas-
cular protection in patients with type 2 diabetes 
with chronic kidney disease.
The observed benefits were obtained on a 
background of renin–angiotensin system block-
ade, the only approved renoprotective medica-
tions in type 2 diabetes, a factor that highlights 
the clinical significance of the findings. In con-
trast to completed cardiovascular outcome trials 
of SGLT2 inhibitors,5-7 our trial included a popu-
lation at high risk for kidney failure and had a 
primary outcome of major renal end points. In 
addition, we found that patients who received 
canaglif lozin (including those who had a re-
duced estimated GFR at baseline) had a lower 
risk of the primary outcome overall than those 
in the placebo group, as well as less end-stage 
kidney disease. These findings were observed 
despite very modest between-group differences 
in blood glucose level, weight, and blood pres-
sure and in contrast to previous concern about 
the initial acute reduction in the estimated GFR 
observed with SGLT2 inhibitors. This suggests 
that the mechanism of benefit is likely to be 
independent of glucose levels and may possibly 
stem from a reduction in intraglomerular pres-
sure,11-13 with other possible mechanisms present-
ly being studied.14-17
Our trial population was also at high risk for 
cardiovascular outcomes, with cardiovascular 
death, myocardial infarction, stroke, or hospital-
ization for heart failure occurring in 13.8% of 
the population over a median of 2.62 years of 
follow-up. The significantly lower rates of car-
diovascular outcomes, including the composite 
of cardiovascular death, myocardial infarction, 
or stroke, in the canagliflozin group in our trial 
are consistent with those observed with cana-
gliflozin in the CANVAS (Canagliflozin Cardio-
vascular Assessment Study) Program,5 despite 
the smaller differences in glycemic control. The 
EMPA-REG OUTCOME trial also showed that 
empagliflozin was superior to placebo,6 and the 
DECLARE–TIMI 58 (Dapagliflozin Effect on Car-
Figure 3. Effects on Albuminuria and Estimated GFR.
Panel A shows the effects of canagliflozin and placebo on the urinary albu-
min-to-creatinine ratio in the intention-to-treat population. Panel B shows 
the change from the screening level in the estimated GFR in the on-treat-
ment population. The I bars indicate the 95% confidence interval in Panel 
A and the standard error in Panel B. The albumin-to-creatinine ratio was 
calculated with albumin measured in milligrams and creatinine measured 
in grams.
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diovascular Events–Thrombolysis in Myocardial 
Infarction 58) trial showed that dapagliflozin 
was noninferior to placebo for this composite 
outcome.7 The reduction in hospitalization for 
heart failure seen in our trial is consistent with 
results of other trials of SGLT2 inhibitors.5-7,18,19
The similar rates of amputation and fracture 
that we observed with canagliflozin and placebo 
are reassuring and consistent with trials of other 
SGLT2 inhibitors6,7,20 but differ from the CANVAS 
Program findings.5 Whether the increased risk 
of lower limb amputation in the CANVAS Pro-
gram was due to differing trial populations or 
protocols or to chance remains unclear. The 
overall safety profile in our trial is otherwise 
consistent with the known adverse effects asso-
ciated with canagliflozin.
This trial has certain limitations. First, the 
trial was stopped early at a planned interim 
analysis, which may have limited the power for 
some secondary outcomes and may increase the 
risk of overestimating effect sizes.21 However, the 
precision of the effect and the consistency with 
the findings of previous large trials of SGLT2 
inhibitors suggest that this limitation is unlikely 
to have a major effect on our findings. Second, 
we did not measure off-treatment estimated GFR 
levels among the patients who had completed the 
trial, so the differences in the estimated GFR 
values at the end of the trial are probably under-
estimations. Third, we excluded patients who had 
very advanced kidney disease (estimated GFR, 
<30 ml per minute per 1.73 m2), nonalbuminuric 
or microalbuminuric disease, and kidney diseases 
believed to be due to conditions other than type 2 
diabetes, so it is not known whether the findings 
can be generalized to such populations.
In conclusion, among patients with type 2 
diabetes and kidney disease, those in the cana-
gliflozin group had a lower risk of kidney failure 
and cardiovascular events than those in the pla-
cebo group at a median follow-up of 2.62 years.
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